Cargando…

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1

BACKGROUND: Form 1 of the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) serves to grade therapies with curative intent. Hitherto only few trials with curative intent have been field tested using form 1. We aimed to evaluate the applicability of the scale and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knapen, Daan Geert, Cherny, Nathan I, Zygoura, Panagiota, Latino, Nicola Jane, Douillard, Jean-Yves, Dafni, Urania, de Vries, Elisabeth G E, de Groot, Derk Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476457/ https://www.ncbi.nlm.nih.gov/pubmed/32893188 http://dx.doi.org/10.1136/esmoopen-2020-000681

Ejemplares similares

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)

PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
por: Paluch-Shimon, Shani, et al.
Publicado: (2020)

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
por: Cherny, N I, et al.
Publicado: (2016)

Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer
por: Sapir, E., et al.
Publicado: (2023)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)

“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores
por: Cherny, N.I., et al.
Publicado: (2022)

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey
por: Banerjee, Susana, et al.
Publicado: (2018)

Prioritising systemic cancer therapies applying ESMO’s tools and other resources to assist in improving cancer care globally: the Kazakh experience
por: Latino, N.J., et al.
Publicado: (2022)

Indicators of integration at ESMO Designated Centres of Integrated Oncology and Palliative Care
por: Hui, David, et al.
Publicado: (2018)

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019)

ESMO gave me a chance to help make a difference: a personal reflection on the occasion of receiving the 2015 ESMO Award
por: Cherny, Nathan I
Publicado: (2016)

Implementation of the ESMO-Magnitude of Clinical Benefit Scale: real world example from the 2022 Israeli National Reimbursement Process
por: Wolf, I., et al.
Publicado: (2022)

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life
por: Ciardiello, Fortunato, et al.
Publicado: (2016)

ESMO Copenhagen 2016: a lung cancer ‘grand cru’
por: Douillard, Jean-Yves
Publicado: (2017)

Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1
por: Pichler, M., et al.
Publicado: (2021)

ESMO Designated Centres of Integrated Oncology and Palliative Care (ESMO DCs): education, research and programme development survey
por: Kreye, G., et al.
Publicado: (2022)

ESMO and WHO: 14 years of working in partnership on cancer control
por: Ullrich, Andreas, et al.
Publicado: (2016)

ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
por: Catanese, Silvia, et al.
Publicado: (2020)

Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015
por: Rolfo, Christian, et al.
Publicado: (2016)

The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey
por: Saloustros, Emmanouil, et al.
Publicado: (2017)

COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)
por: Castelo-Branco, L., et al.
Publicado: (2022)

ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe
por: Cherny, N I, et al.
Publicado: (2017)

From ESMO 2022
por: Romero, Diana
Publicado: (2022)

Conducting research in individual patients: lessons learnt from two series of N-of-1 trials
por: Wegman, Anke CM, et al.
Publicado: (2006)

Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines
por: Zarkavelis, G., et al.
Publicado: (2022)

The implementation of the coaching on lifestyle (CooL) intervention: lessons learnt
por: van Rinsum, Celeste, et al.
Publicado: (2019)

Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty
por: Lordick, Florian, et al.
Publicado: (2019)

Report on the status of women occupying leadership roles in oncology
por: Hofstädter-Thalmann, Eva, et al.
Publicado: (2018)

Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain
por: Roitberg, F., et al.
Publicado: (2023)

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
por: Curigliano, G., et al.
Publicado: (2020)

From ESMO TAT 2021
por: Killock, David
Publicado: (2021)

From the ESMO Congress 2021
por: Sidaway, Peter
Publicado: (2021)

Lessons learnt from Run 1: SUSY perspective
por: Canepa, Anadi
Publicado: (2014)

SARS Lessons learnt
por: Seto, W.H.
Publicado: (2015)

ESMO Leaders Generation Programme: an alumni insight
por: Arruda, Leticia De Mattos, et al.
Publicado: (2018)

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?
por: Rodriguez, Adela, et al.
Publicado: (2021)

The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate
por: Garassino, M.C., et al.
Publicado: (2021)

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy
por: Perez-Gracia, Jose Luis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pqlk0l0jf25fb5g30micb714db